Novartis begins Zolgensma study after FDA’s hold lifts

Novartis begins Zolgensma study after FDA’s hold lifts

Aiming to expand the use of Zolgensma, Novartis has announced the launch of a new phase three study following the FDA’s decision to remove restrictions and partial clinical trial hold. Novartis plans to evaluate the use of Zolgensma to treat patients (aged 2-18) for...
Bristol Myers Opdivo Wins The EC Approval for GEJ Cancer

Bristol Myers Opdivo Wins The EC Approval for GEJ Cancer

The European Commmision (EC) has granted Bristol Myers approval for Opdivo (nivolumab) to treat adult esophageal or gastroesophageal junction (GEJ) cancer who have pathologic disease after previous neoadjuvant chemoradiotherapy (CRT).  With the approval based on the...